These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27864207)

  • 1. Clinical and regulatory considerations in pharmacogenetic testing.
    Schuck RN; Marek E; Rogers H; Pacanowski M
    Am J Health Syst Pharm; 2016 Dec; 73(23):1999-2006. PubMed ID: 27864207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era.
    Evans BJ
    Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics: from discovery to patient care.
    Shin J; Kayser SR; Langaee TY
    Am J Health Syst Pharm; 2009 Apr; 66(7):625-37. PubMed ID: 19299369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Personalizing medicine with clinical pharmacogenetics.
    Scott SA
    Genet Med; 2011 Dec; 13(12):987-95. PubMed ID: 22095251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An outsider's viewpoint: the FDA should regulate clinical pharmacogenetic/genomic tests, but...
    O'Kane D
    Clin Pharmacol Ther; 2010 Dec; 88(6):746-8. PubMed ID: 21081942
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical Trial Designs to Support Clinical Utility of Pharmacogenomic Testing.
    Drozda K; Pacanowski MA
    Pharmacotherapy; 2017 Sep; 37(9):1000-1004. PubMed ID: 28605049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic Testing: Why Is It So Disappointing?
    Limandri BJ
    J Psychosoc Nurs Ment Health Serv; 2019 Apr; 57(4):9-12. PubMed ID: 30933297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines.
    Pritchard D; Patel JN; Stephens LE; McLeod HL
    Am J Health Syst Pharm; 2022 Jun; 79(12):993-1005. PubMed ID: 35230418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics in drug regulation: promise, potential and pitfalls.
    Shah RR
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1617-38. PubMed ID: 16096112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should pharmacogenomic studies be required for new drug approval?
    Relling MV; Hoffman JM
    Clin Pharmacol Ther; 2007 Mar; 81(3):425-8. PubMed ID: 17339872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for pharmacogenetic testing in clinical practice guidelines in the US.
    Hertz DL; Bousman CA; McLeod HL; Monte AA; Voora D; Orlando LA; Crutchley RD; Brown B; Teeple W; Rogers S; Patel JN
    Am J Health Syst Pharm; 2024 Aug; 81(16):672-683. PubMed ID: 38652504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implementation of genetic testing in medicine: a US regulatory science perspective.
    Lesko LJ; Schmidt S
    Br J Clin Pharmacol; 2014 Apr; 77(4):606-11. PubMed ID: 24286486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Facilitators and Barriers to the Adoption of Pharmacogenetic Testing in an Inner-City Population.
    Lee YM; Manzoor BS; Cavallari LH; Nutescu EA
    Pharmacotherapy; 2018 Feb; 38(2):205-216. PubMed ID: 29286540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic Information in Clinical Guidelines: The European Perspective.
    Swen JJ; Nijenhuis M; van Rhenen M; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Guchelaar HJ;
    Clin Pharmacol Ther; 2018 May; 103(5):795-801. PubMed ID: 29460273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications.
    Malik S; Verma P; Ruaño G; Al Siaghy A; Dilawar A; Bishop JR; Strawn JR; Namerow LB
    J Child Adolesc Psychopharmacol; 2024 Feb; 34(1):4-20. PubMed ID: 38377525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee.
    Vassy JL; Stone A; Callaghan JT; Mendes M; Meyer LJ; Pratt VM; Przygodzki RM; Scheuner MT; Wang-Rodriguez J; Schichman SA;
    Genet Med; 2019 Feb; 21(2):382-390. PubMed ID: 29858578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crunch time for multiple-gene tests.
    Gewin V
    Nature; 2007 Jan; 445(7126):354-5. PubMed ID: 17251949
    [No Abstract]   [Full Text] [Related]  

  • 18. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?
    de Leon J; Spina E
    Expert Rev Clin Pharmacol; 2016; 9(3):351-4. PubMed ID: 26580456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers.
    Keeling NJ; Rosenthal MM; West-Strum D; Patel AS; Haidar CE; Hoffman JM
    Genet Med; 2019 May; 21(5):1224-1232. PubMed ID: 31048813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Pharmacogenetic Information in Food and Drug Administration Drug Labeling and the Table of Pharmacogenetic Associations.
    Cheng CM; So TW; Bubp JL
    Ann Pharmacother; 2021 Oct; 55(10):1185-1194. PubMed ID: 33384014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.